BioCentury
ARTICLE | Company News

Dainippon Sumitomo, Shionogi sales and marketing update

December 3, 2012 8:00 AM UTC

Dainippon and partner Shionogi plan to launch hypertension drug Aimix amlodipine besilate/irbesartan in Japan on Dec. 19. The product is an oral combination of amlodipine besilate, a calcium channel blocker, and irbesartan, an angiotensin II type 1 (AT1) receptor (AGTR1) antagonist. The combination tablets will be available in a high-dose formulation of 10 mg amlodipine besilate and a low-dose formulation of 5 mg amlodipine besylate. The partners said the National Health Insurance (NHI) reimbursement price for a once-daily, high-dose tablet is ¥173.40 ($2.12), while a low-dose tablet will have a reimbursement price of ¥150.40 ($1.83). Japan approved the products in September. Dainippon and Shionogi will co-market the product in Japan under a June deal (see BioCentury, June 11 & Oct. 8). ...